• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Did Lower Nine Month Earnings Just Shift Pharma Mar's (BME:PHM) Investment Narrative?

    Simply Wall St·11/05/2026 09:32:35
    Listen to the news
    • Pharma Mar reported earnings for the nine months to 30 September 2026, with net income of €8.7 million compared with €15.32 million in the same period a year earlier.
    • The drop in net income suggests higher costs, weaker royalties or product sales, or a different revenue mix are weighing on Pharma Mar’s profitability in 2026.
    • This raises questions about how Pharma Mar’s investment narrative holds up against this year’s sharply lower nine month net income performance.

    Compare how Pharma Mar’s earnings setback aligns with other healthcare stocks experiencing similar profit pressure by using our curated 129 healthcare AI stocks as an initial watchlist.

    Pharma Mar Investment Narrative Recap

    To stay on board with Pharma Mar, you need to believe the oncology portfolio can offset lumpier earnings and a narrow product base. The nine month net income of €8.7 million, against €15.32 million a year earlier, does not on its own rewrite that story. It does highlight how dependent the business still is on royalty flows and a small set of therapies.

    The most immediate swing factor remains execution on Zepzelca first line maintenance in the U.S. and Europe, along with Yondelis resilience against generics. The biggest risk sits in the same place. Any clinical or regulatory setback on these few assets, or sharper pricing pressure, could matter more than a single year of softer profit.

    The Q3 2026 earnings release on 29 October is the announcement that really matters here. It updates the scorecard on how Pharma Mar is converting its oncology pipeline and recent approvals into actual profit, and how royalty and product revenue lines are holding up against competition and costs.

    For catalysts, this report helps you judge whether earlier signs of strong royalty growth and expanding margins are showing through in current figures, or whether momentum is stalling. It also gives context for risks flagged by analysts, including the concentration in a few drugs and the role of non cash earnings in past results.

    What Pharma Mar’s Long Range Consensus Is Asking You To Believe

    Pharma Mar's narrative projects €411.9 million revenue and €222.2 million earnings by 2029. This implies 23.5% yearly revenue growth and an earnings increase of about €166 million from €56.1 million today.

    Analysts are effectively asking you to underwrite a shift from a mid sized oncology specialist with €56.1 million in earnings today to a business generating €222.2 million in profit by 2029. That jump assumes both strong compounding in revenue and a lift in profit margins from 25.7% to 53.9%, so a lot of the story rests on operating leverage from the existing product set rather than only on new launches.

    Consensus also bakes in revenue reaching €411.9 million in 2029, which lines up with the assumed 23.5% annual expansion over the next three years. For you as a holder or potential buyer, the key question is whether Pharma Mar’s oncology portfolio and royalty streams can realistically support that kind of top line curve without requiring unsustainably high spending or constant new indications just to keep pace.

    The gap between current earnings and the 2029 forecast is wide enough that disagreement among analysts starts to matter. The most bullish forecast at €469.7 million in earnings and the most cautious at €151.9 million describe very different futures for Pharma Mar, so any personal valuation work benefits from stress testing both sides of that range rather than relying on the €222.2 million midpoint alone.

    Valuation thinking in the analyst models leans on Pharma Mar trading on a P/E of 10.2x those 2029 earnings, which is lower than both its current 21.0x multiple and the cited 18.4x for the wider GB biotechs group. That implies the current share price of €68.05 and the consensus target of €102.44, which is 33.6% higher, depend on you being comfortable with earnings more than tripling and the market still paying a discounted multiple for that future profit stream.

    Uncover why Pharma Mar's fair value indicates a 53% potential upside to its current price that could narrow quickly.

    BME:PHM 1-Year Stock Price Chart
    BME:PHM 1-Year Stock Price Chart

    Exploring Other Perspectives

    You now have a live test of the bearish story. Those lowest analysts were already cautious, with revenue pencilled at about €386.2 million and earnings at €149.9 million by 2029, and the latest nine month profit of €8.7 million could push them further. Treat Pharma Mar as a case study in how sharply views can diverge and explore several narratives before deciding what makes sense to you.

    Explore 4 other Pharma Mar fair value estimates, including one that suggests it could be worth just €85.50!

    Reach Your Own Conclusion

    Don't just follow the ticker; dig into the data and build a conviction that's truly your own.

    Looking For More Investment Ideas Beyond Pharma Mar?

    If this update on Pharma Mar has sharpened your thinking about risk, reward, and earnings quality, it can help to compare those traits with other listed businesses. Use the Simply Wall St Screener to build a broader watchlist that matches the kind of opportunities you want to research next.